nach oben

Die Innere Medizin

Erschienen in:

07.07.2022 | COVID-19 | Schwerpunkt: Long-COVID

Stellenwert der COVID-19-Impfung im Kontext von Long-COVID

verfasst von: Dr. med. Stilla Bauernfeind, M.Sc., Barbara Schmidt

Erschienen in: Die Innere Medizin | Ausgabe 8/2022

Einloggen, um Zugang zu erhalten

Zusammenfassung

Strategien zum Umgang mit Long-COVID (COVID „coronavirus disease“) sind bislang nicht verfügbar. Eine der aktuell geprüften Optionen ist die COVID-19-Impfung, sowohl präventiv als auch therapeutisch. Die Bewertung der vorhandenen Studien ist durch uneinheitliche Definitionen erschwert. Es gibt jedoch Hinweise, dass die (vollständige) COVID-19-Impfung nicht nur die symptomatische Infektion verhindern kann, sondern auch das Risiko für Long-COVID bei Durchbruchinfektionen zu reduzieren vermag. Bei Patienten mit Long-COVID führt die anschließende (einfache und/oder zweifache) COVID-19-Impfung teilweise zu einer Symptommodifikation, die bisweilen nur passager ist. Ein therapeutischer Effekt kann aus der vorliegenden Evidenz allerdings nicht sicher abgeleitet werden.

World Health Organization (2021) A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021. https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1. Zugegriffen: 29. Apr. 2022

National Institute for Health and Care Excellence (NICE) (2020) Scottish intercollegiate guidelines network (SIGN) and royal college of general practitioners (RCGP). COVID-19 rapid guideline: managing the long-term effects of COVID-19. https://www.nice.org.uk/guidance/ng188/resources/covid19-rapid-guideline-managing-the-longterm-effects-of-covid19-pdf-51035515742. Zugegriffen: 29. Apr. 2022

Koczulla AR, Ankermann T, Behrends U, Berlit P, Böing S, Brinkmann F, Franke C, Glöckl R, Gogoll C, Hummel T, Kronsbein J, Maibaum T, Peters EMJ, Pfeifer M, Platz T, Pletz M, Pongratz G, Powitz F, Rabe KF, Scheibenbogen C, Stallmach A, Stegbauer M, Wagner HO, Waller C, Wirtz H, Zeiher A, Zwick R (2021) S1-Leitlinie Post-COVID/Long-COVID. https://www.awmf.org/uploads/tx_szleitlinien/020-027l_S1_Post_COVID_Long_COVID_2021-07.pdf. Zugegriffen: 30. Apr. 2021

Harrison S, Walters B, Simmons Z, Cook M, Clark R (2022) The effectiveness of vaccination against long COVID; A rapid evidence briefing. https://ukhsa.koha-ptfs.co.uk/cgi-bin/koha/opac-retrieve-file.pl?id=fe4f10cd3cd509fe045ad4f72ae0dfff. Zugegriffen: 23. Apr. 2022

The Public Health Agency of Canada (2022) Are there clinically significant interactions between COVID-19 vaccination and post-COVID-19 condition (long COVID)? https://www.canada.ca/content/dam/phac-aspc/documents/services/diseases/2019-novel-coronavirus-infection/canadas-reponse/summaries-recent-evidence/evidence-brief-associations-safety-covid-19-vaccination-post-condition/evidence-brief-associations-safety-covid-19-vaccination-post-condition.pdf. Zugegriffen: 23. Apr. 2022

Ledford H (2021) Do vaccines protect against long COVID? What the data say. Nature 599:546–548CrossRef

Gaebler C, Wang Z, Lorenzi JCC et al (2021) Evolution of antibody immunity to SARS-CoV‑2. Nature 591:639–644CrossRef

Bertin D, Kaphan E, Weber S et al (2021) Persistent IgG anticardiolipin autoantibodies are associated with post-COVID syndrome. Int J Infect Dis 113:23–25CrossRef

Richter AG, Shields AM, Karim A et al (2021) Establishing the prevalence of common tissue-specific autoantibodies following severe acute respiratory syndrome coronavirus 2 infection. Clin Exp Immunol 205:99–105CrossRef

10.

Anaya J‑M, Monsalve DM, Rojas M et al (2021) Latent rheumatic, thyroid and phospholipid autoimmunity in hospitalized patients with COVID-19. J Transl Autoimmun 4:100091CrossRef

11.

Wallukat G, Hohberger B, Wenzel K et al (2021) Functional autoantibodies against G‑protein coupled receptors in patients with persistent Long-COVID-19 symptoms. J Transl Autoimmun 4:100100CrossRef

12.

Murphy WJ, Longo DL (2022) A possible role for anti-idiotype antibodies in SARS-coV‑2 infection and vaccination. N Engl J Med 386:394–396CrossRef

13.

Arthur JM, Forrest JC, Boehme KW et al (2021) Development of ACE2 autoantibodies after SARS-CoV‑2 infection. PLoS ONE 16:e257016CrossRef

14.

Haran JP, Bradley E, Zeamer AL et al (2021) Inflammation-type dysbiosis of the oral microbiome associates with the duration of COVID-19 symptoms and long COVID. JCI Insight 6:e152346CrossRef

15.

Liu Q, Mak JWY, Su Q et al (2022) Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome. Gut 71:544–552CrossRef

16.

Gold JE, Okyay RA, Licht WE, Hurley DJ (2021) Investigation of long COVID prevalence and its relationship to Epstein-Barr virus reactivation. Pathogens 10:763CrossRef

17.

Yong SJ (2021) Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis 53:737–754CrossRef

18.

Katella K (2021) Why vaccines may be helping some with long COVID. https://www.yalemedicine.org/news/vaccines-long-covid. Zugegriffen: 15. Mai 2022

19.

Antonelli M, Penfold RS, Merino J et al (2022) Risk factors and disease profile of post-vaccination SARS-coV‑2 infection in UK users of the COVID symptom study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis 22:43–55CrossRef

20.

Al-Aly Z, Bowe B, Xie Y (2022) Long COVID after breakthrough SARS-CoV‑2 infection. https://www.nature.com/articles/s41591-022-01840-0. Zugegriffen: 29. Mai 2022

21.

Herman B, Viwattanakulvanid P, Dzulhadj A, Oo AC, Patricia K, Pongpanich S (2022) Effect of full vaccination and post-COVID olfactory dysfunction in recovered COVID-19 patient. A retrospective longitudinal study with propensity matching. http://medrxiv.org/lookup/doi/10.1101/2022.01.10.22269007. Zugegriffen: 16. Apr. 2022

22.

Senjam SS, Balhara YPS, Kumar P et al (2021) Assessment of post COVID-19 health problems and its determinants in north India: a descriptive cross section study. http://medrxiv.org/lookup/doi/10.1101/2021.10.03.21264490. Zugegriffen: 13. Apr. 2022

23.

Ayoubkhani D, Bosworth ML, King S et al (2022) Risk of Long Covid in people infected with SARS-CoV‑2 after two doses of a COVID-19 vaccine: community-based, matched cohort study. http://medrxiv.org/lookup/doi/10.1101/2022.02.23.22271388. Zugegriffen: 15. Mai 2022

24.

Kuodi P, Gorelik Y, Zayyad H et al (2022) Association between vaccination status and reported incidence of post-acute COVID-19 symptoms in Israel: a cross-sectional study of patients tested between March 2020 and November 2021. http://medrxiv.org/lookup/doi/10.1101/2022.01.05.22268800. Zugegriffen: 13. Apr. 2022

25.

Simon MA, Luginbuhl RD, Parker R (2021) Reduced incidence of long-COVID symptoms related to administration of COVID-19 vaccines both before COVID-19 diagnosis and up to 12 weeks after. http://medrxiv.org/lookup/doi/10.1101/2021.11.17.21263608. Zugegriffen: 13. Apr. 2022

26.

Taquet M, Dercon Q, Harrison PJ (2022) Six-month sequelae of post-vaccination SARS-CoV‑2 infection: a retrospective cohort study of 10,024 breakthrough infections. Brain Behav Immun 103:154–162CrossRef

27.

Arjun MC, Singh AK, Pal D et al (2022) Prevalence, characteristics, and predictors of long COVID among diagnosed cases of COVID-19. http://medrxiv.org/lookup/doi/10.1101/2022.01.04.21268536. Zugegriffen: 13. Apr. 2022

28.

Arnold DT, Milne A, Samms E, Stadon L, Maskell NA, Hamilton FW (2021) Symptoms after COVID-19 vaccination in patients with persistent symptoms after acute infection: a case series. Ann Intern Med 174:1334–1336CrossRef

29.

Ayoubkhani D, Bermingham C, Pouwels KB et al (2022) Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study. BMJ 377:e69676. https://doi.org/10.1136/bmj-2021-069676CrossRefPubMed

30.

Gaber TA-ZK, Ashish A, Unsworth A, Martindale J Are mRNA covid 19 vaccines safe in long covid patients? A health care workers perspective. https://www.bjmp.org/content/are-mrna-covid-19-8. 9. vaccines-safe-long-covid-patients-health-care-workers-perspective. Zugegriffen: 13. Apr. 2022

31.

Strain WD, Sherwood O, Banerjee A, Van der Togt V, Hishmeh L, Rossman J (2022) The impact of COVID vaccination on symptoms of long COVID: an international survey of people with lived experience of long COVID. Vaccines 10:652CrossRef

32.

Scherlinger M, Pijnenburg L, Chatelus E et al (2021) Effect of SARS-CoV‑2 vaccination on symptoms from post-acute sequelae of COVID-19: results from the nationwide VAXILONG study. Vaccines 10:46CrossRef

33.

Tran V‑T, Perrodeau E, Saldanha J, Pane I, Ravaud P (2021) Efficacy of COVID-19 vaccination on the symptoms of patients with long COVID: a target trial emulation using data from the compare e‑cohort in France. https://www.ssrn.com/abstract=3932953. Zugegriffen: 13. Apr. 2022

34.

Wanga V, Chevinsky JR, Dimitrov LV et al (2021) Long-term symptoms among adults tested for SARS-CoV-2—United States, January 2020–April 2021. Mmwr Morb Mortal Wkly Rep 70:1235–1241CrossRef

35.

Nehme M, Braillard O, Salamun J et al (2022) Symptoms after COVID-19 vaccination in patients with post-acute sequelae of SARS-CoV‑2. J Gen Intern Med 37:1585–1588CrossRef

36.

Whittaker HR, Gulea C, Koteci A et al (2021) GP consultation rates for sequelae after acute covid-19 in patients managed in the community or hospital in the UK: population based study. BMJ. https://doi.org/10.1136/bmj-2021-065834CrossRefPubMed

37.

Peghin M, De Martino M, Palese A et al (2022) Post-COVID-19 syndrome and humoral response association after one year in vaccinated and unvaccinated patients. Clin Microbiol Infect. https://doi.org/10.1016/j.cmi.2022.03.016CrossRefPubMedPubMedCentral

38.

Wisnivesky JP, Govindarajulu U, Bagiella E et al (2022) Association of vaccination with the persistence of post-COVID symptoms. https://link.springer.com/10.1007/s11606-022-07465-w. Zugegriffen: 12. Mai 2022

39.

Raw RK, Kelly CA, Rees J, Wroe C, Chadwick DR (2021) Previous COVID-19 infection, but not Long-COVID, is associated with increased adverse events following BNT162b2/Pfizer vaccination. J Infect 83:381–412CrossRef

40.

Polack FP, Thomas SJ, Kitchin N et al (2020) Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 383:2603–2615CrossRef

41.

Baden LR, El Sahly HM, Essink B et al (2021) Efficacy and safety of the mRNA-1273 SARS-CoV‑2 vaccine. N Engl J Med 384:403–416CrossRef

42.

Voysey M, Clemens SAC, Madhi SA et al (2021) Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397:99–111CrossRef

43.

Sadoff J, Gray G, Vandebosch A et al (2021) Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med 384:2187–2201CrossRef

44.

Heath PT, Galiza EP, Baxter DN et al (2021) Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N Engl J Med 385:1172–1183CrossRef

45.

Iqbal FM, Lam K, Sounderajah V, Clarke JM, Ashrafian H, Darzi A (2021) Characteristics and predictors of acute and chronic post-COVID syndrome: a systematic review and meta-analysis. EClinicalMedicine 36:100899CrossRef

46.

Sudre CH, Murray B, Varsavsky T et al (2021) Attributes and predictors of long COVID. Nat Med 27:626–631CrossRef

47.

Couzin-Frankel J, Vogel G (2022) Vaccines may cause rare, Long Covid–like symptoms. Science 375:364–366CrossRef

48.

Gießelmann K, Martin M (2022) Post-Vac-Syndrom: Seltene Folgen nach Impfung. Dtsch Arztebl 119(19):A-862–B-714

49.

Massey D, Berrent D, Akrami A et al (2021) Change in symptoms and immune response in people with post-acute sequelae of SARS-Cov‑2 infection (PASC) after SARS-Cov‑2 vaccination. http://medrxiv.org/lookup/doi/10.1101/2021.07.21.21260391. Zugegriffen: 13. Apr. 2022

50.

University of Oxford (2021) New research studies to help diagnose and treat Long COVID funded by NIHR; Impact of COVID-19 vaccination on preventing Long COVID: a population-based cohort study using linked NHS data. https://www.ox.ac.uk/news/2021-07-19-new-research-studies-help-diagnose-and-treat-long-covid-funded-nihr. Zugegriffen: 30. Apr. 2022

51.

NIH RECOVER (2022) A multi-site observational study of post-acute sequelae of SARS-CoV‑2 infection in adults. https://recovercovid.org/docs/Adult.Protocol.v5.1.pdf. Zugegriffen: 30. Apr. 2022

52.

World Health Organization (2021) Global COVID-19 clinical platform case report form (CRF) for post COVID condition (post COVID-19 CRF). https://apps.who.int/iris/bitstream/handle/10665/345298/WHO-2019-nCoV-Post_COVID-19_CRF-2021.1-eng.pdf?sequence=1&isAllowed=y. Zugegriffen: 23. Apr. 2022

Titel: Stellenwert der COVID-19-Impfung im Kontext von Long-COVID
verfasst von: Dr. med. Stilla Bauernfeind, M.Sc.
Barbara Schmidt
Publikationsdatum: 07.07.2022
Verlag: Springer Medizin
Schlagwörter: COVID-19
SARS-CoV-2
SARS-CoV
Impfungen
COVID-19-Impfung
Long-COVID
Erschienen in: Die Innere Medizin / Ausgabe 8/2022
Print ISSN: 2731-7080
Elektronische ISSN: 2731-7099
DOI: https://doi.org/10.1007/s00108-022-01368-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Stellenwert der COVID-19-Impfung im Kontext von Long-COVID

Zusammenfassung

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2022

Long-COVID – eine neue Herausforderung

Mitteilungen der DGIM

„Double hit": Was verursachte die embolischen Ereignisse?

Fortbildungen und Kongresse des BDI

Ihre Diagnose? Vor Kurzem aufgetretene massive Claudicatio intermittens bei jungem Mann

Mitteilungen des BDI

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin